Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by 6c; Guides FY18 Relatively In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jazz Pharmaceuticals (JAZZ) PT Raised to $199 at BMO Capital
February 28, 2018 6:59 AM ESTBMO Capital raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $199.00 (from $196.00) while maintaining an Outperform rating.
Analyst Gary Nachman commented, "JAZZ reported 4Q revenue of $436mm vs. BMO/consensus of $438mm/442mm and adj. EPS of $2.95 vs. BMO/consensus of... More
